Sinovac Biotech Ltd., listed on the Nasdaq Global Select Market (NasdaqGS: SVA), is a high-tech biopharmaceutical company headquartered in Beijing. Through its wholly owned subsidiary, Sinovac Biotech (Hong Kong) Limited, Sinovac Biotech Co., Ltd. owns five branches as well as four production bases located in Haidan, Changping and Daxing districts of Beijing, and Dalian of Liaoning. Following the mission of “Supply Vaccines to Eliminate Human Diseases", Sinovac is committed to the research, development, manufacturing and commercialization of vaccines for humans, as well as providing services for disease control and prevention. Sinovac’s product portfolio currently includes: the Covid-19 Vaccine (Vero Cell), Inactivated (CoronaVac®); Enterovirus Type 71 Vaccine (Vero Cell), Inactivated (Inlive®, a new drug under “Category 1 Preventative Biological Products); China’s first WHO pre-qualified Hepatitis A Vaccine (Human Diploid Cell), Inactivated (Healive®), etc. Furthermore, Sinovac has been making great contributions to disease control and prevention in China and across the world. Sinovac’s vaccines have successfully obtained market authorizations and/or product registration licenses from dozens of countries around the world.